27th week of 2010 patent applcation highlights part 30 |
Patent application number | Title | Published |
20100172924 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-07-08 |
20100172925 | HLA-A2-RESTRICTED T-CELL EPITOPES OF THE RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN AS PEPTIDE-BASED VACCINES - Respiratory syncytial virus (RSV) fusion protein-specific T-cell epitopes as peptide-based vaccines are disclosed. The isolated peptide contains a human HLA restricted CD8+ T-cell epitope that is specific to RSV F protein. The length of the peptide is no more than 9 or 10 amino acid residues. The peptide may be employed as an immunogen to stimulate cytotoxic T cells, indirectly activate helper T cells type 1, and cause release of cytokines from T cells. | 2010-07-08 |
20100172926 | ANTHRAX COMPOSITIONS AND METHODS OF USE AND PRODUCTION - Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by | 2010-07-08 |
20100172927 | Vaccines Against Chlamydial Infection - Methods and compositions for the treatment or prevention of ocular | 2010-07-08 |
20100172928 | Recombinant viral-based malaria vaccines - The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different | 2010-07-08 |
20100172929 | Malaria Vaccines - The invention provides isolated placental | 2010-07-08 |
20100172930 | TRANSFECTION COMPLEXES - The invention provides a peptide having at least 3 amino acids comprising an amino acid sequence selected from | 2010-07-08 |
20100172931 | Pharmaceutical Composition Containing the NMB1796 Protein - The present invention is related to field of medicine, particularly to the development of pharmaceutical composition containing the NMB1796 protein. The composition described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. The NMB1796 protein was identified as a | 2010-07-08 |
20100172932 | USE OF ISLET GLUCOSE-6-PHOSPHATASE RELATED PROTEIN AS A DIAGNOSTIC TOOL AND THERAPEUTIC TARGET FOR AUTOIMMUNE DIABETES - A method and compositions for detecting autoimmunity to islet glucose-6-phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD | 2010-07-08 |
20100172933 | Recombinant vectors based on the modified vaccinia ankara (mva) virus as vaccines against lieshmaniasis - The invention relates to recombinant vectors based on the Modified Vaccinia Ankara (MVA) virus as vaccines against leishmaniasis. The inventive vectors contain sequences encoding the LACK protein, which are preferably inserted into the hemagglutinin locus of the virus under the control of a promoter, which enables the expression of same throughout the infection cycle of the virus. The invention comprises stable, safe vectors which elicit a strong immune response that provides protection against leishmaniasis and which, as such, are particularly suitable for use in vaccination against said disease, especially in humans, s well as in the largest animal reservoir of said anthropozoonosis, i.e. dogs. | 2010-07-08 |
20100172934 | METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES - The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity. | 2010-07-08 |
20100172935 | Method for viral inoculation of the vestibular region of the nares - A method of inoculation of the vestibular region of the nares with a virus, provides the steps of: applying the virus exclusively to the anterior vestibular region of the nares; and avoiding penetration of the virus beyond the vestibular region during application. | 2010-07-08 |
20100172936 | CHIMERIC PAPILLOMAVIRUS-LIKE PARTICLES - The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines. | 2010-07-08 |
20100172937 | ENVELOPED VIRUS NEUTRALIZING COMPOUNDS - Methods for reducing infectivity by providing an enveloped virus neutralizing compound (EVNC) are provided. Methods of preparing a vaccine, vaccine formulations, and methods of immunizing a subject a further provided. Methods of disinfecting a surface are still further provided. In some embodiments, compositions comprising an isolated and purified bioactive EVNC agent are provided. | 2010-07-08 |
20100172938 | MODIFIED BACTERIAL SURFACE LAYER PROTEINS - Modified bacterial surface layer (S-layer) proteins are disclosed where the modification is the insertion, at an internal location, of a heterologous polypeptide, or polypeptide of interest. The polypeptide is a binding or target protein, such as an antigen or antibody, or part thereof, in particular a bacterial antigen (e.g. from | 2010-07-08 |
20100172939 | Treating neoplasms with neurotoxin - The present invention provides a method of treating a neoplasm using a neurotoxin, preferably botulinum toxin. Neurotoxin administered around a neoplasm acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze neoplastic cells through efferent channels leaving the neoplasm to distant sites. The present invention also provides a method of administering botulinum toxin at sites distant from the neoplasm, thereby enhancing cellular and humoral immunologic functions, which further contribute to neoplastic cell death. Following administration of botulinum toxin around or distant to a neoplasm as described herein, local, regional, and distant spread of neoplastic cells is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other diseases that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV. | 2010-07-08 |
20100172940 | TREATMENT OF SOFT TISSUE INJURY USING HYALURONIC ACID AND BOTULINUM TOXIN - There is provided a method for supporting soft tissue in a mammal. The method may in aspects treat acutely or chronically injured soft tissue in an animal or human, the method comprising administering a therapeutically effective amount of HA and botulinum toxin in combination around the injured soft tissue. The method is useful for the treatment of sprain and strain in an animal such as a human. | 2010-07-08 |
20100172941 | Adjuvant Compositions and Methods of Use - This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions. | 2010-07-08 |
20100172942 | MULTI-MEMBRANE IMMUNOISOLATION SYSTEM FOR CELLULAR TRANSPLANT - This invention relates to an immunoisolation encapsulation system that protects cellular transplants and thus allows cell function and survival without the need of immunosuppression. The immunoisolation system is a multi-component, multi-membrane capsule that allows optimization of multiple design parameters independently for reproducible functions in large animal models. | 2010-07-08 |
20100172943 | PEPTIDE NANOPARTICLES AND USES THEREFOR - The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin. | 2010-07-08 |
20100172944 | COMBINATION OF MONOSACCHARIDES WITH SUNSCREENS AND USE THEREOF - The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one sunscreen. The present invention also relates to the use of such a composition. | 2010-07-08 |
20100172945 | EXTRUDED DELIVERY SYSTEM - A solid delivery system for an oily active ingredient, comprises an extrudate of a melt-emulsion wherein the continuous phase of the emulsion comprises a matrix material and the dispersed phase comprises an oily active material and an effective amount of a viscosity modifying ingredient such as ethyl cellulose. | 2010-07-08 |
20100172946 | MATRIX-TYPE TRANSDERMAL DRUG DELIVERY SYSTEM AND PREPARATION METHOD THEREOF - A matrix-type transdermal drug delivery system including capsaicin or a capsaicin derivative as an active component and used for treating neuropathy, pain, and inflammation and a preparation method thereof are provided. The matrix-type transdermal drug delivery system includes: a drug protecting layer; a matrix layer formed on the drug protecting layer and including 0.1-25 wt % of capsaicin or a capsaicin derivative, 40-95 wt % of an adhesive including a water-insoluble acrylic polymer, 1-30 wt % of an alcohol having a molecular weight of 600 Daltons or less, 0.1-20 wt % of a nonionic surfactant, and 0.1-20 wt % of a solubilizing agent including a hydrophilic polymer; and a release liner formed on the matrix layer, and is used for treating neuropathy, pain, or inflammation. | 2010-07-08 |
20100172947 | Pediculicidal Process And Composition - Pediculicidal process which make it possible to combat the growth of the louse | 2010-07-08 |
20100172948 | Antimicrobial Coatings for Treatment of Surfaces in a Building Setting and Method of Applying Same - Antimicrobial coatings to protect surfaces and a method of applying such a coating are disclosed. An antimicrobial coating may be applied to a surface, such as the interior surface of a building's exterior wall. The interior surface must be accessed, and then an antimicrobial coating is provided and applied. The antimicrobial coating includes an inorganic antimicrobial additive and a colloidal polymeric medium. The inorganic antimicrobial additive may be silver, platinum, gold, palladium, copper, zinc, boron, or a compound of any of those elements. By including an ultraviolet tracer or color dye additive in the coating, it is possible to detect the coating at any time, provided that the surface is accessed. | 2010-07-08 |
20100172949 | CONSENSUS PEPTIDE - The present invention relates to artificial peptides optimized for the induction and/or stimulation of mineralization and/or biomineralization. The invention also relates to the use of these artificial peptides for the induction and/or stimulation of mineralization and/or biomineralization in vivo and in vitro. | 2010-07-08 |
20100172950 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTRAN WITH A MOLECULAR WEIGHT OF 1.0-100 KDA AND PROCESSES FOR THEIR PREPARATION - A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition. | 2010-07-08 |
20100172951 | Enhanced Medical Implant - A medical implant comprising in combination a synthetic, biological, or autologous matrix (or scaffold) and pluripotent stem cells derived from human teeth. Stem cells are harvested from the dental pulp of extracted wisdom teeth. After the stem cells are removed, the hard tooth is ground into a base material for the manufacture of a porous matrix bone into which the stem cells can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair. | 2010-07-08 |
20100172952 | Electrospun Scaffolds And Methods Of Generating And Using Same - A porous scaffold is disclosed, the porous scaffold comprising electrospun polymeric nanofibers, wherein an average diameter of a pore of the porous scaffold is about 300 μm is disclosed. An average diameter of the polymeric nanofibers ranges from about 100 to 400 nm. The scaffold may comprise a plurality of particles, the particles being greater than about 1 μm in diameter. Methods of fabricating scaffolds, methods for generating tissue and methods of using scaffolds for tissue reconstruction are also disclosed. | 2010-07-08 |
20100172953 | Biopolymer Based Implantable Degradable Devices - Implantable degradable devices for tissue repair or reconstruction comprising biopolymers, as well as to methods of manufacture and use thereof. The implantable device is formed by the application of pressure and the device may include up to about 65% by weight of water, based on the total weight of the implantable degradable fastening device. Methods for making implantable, degradable devices from biopolymers by application of pressure are also disclosed. The invention provides the ability to customize the device in various ways to influence properties such as mechanical strength, degradation rate and swellability. | 2010-07-08 |
20100172954 | IRRADIATED IMPLANTABLE BONE MATERIAL - A method for making an implantable bone material. The method includes providing a bone composition consisting essentially of demineralized human bone, and irradiating the composition at a temperature less than about 0° C. | 2010-07-08 |
20100172955 | BIODEGRADABLE MATERIAL COMPONENTS - A biodegradable material for use in making items usable in surgery and related fields of medicine. The material comprising a bioabsorbable thermoplastic polymer component and a bioactive filler material. In components made of the material particles of the filler material occur embedded within the surface of the components. | 2010-07-08 |
20100172956 | DISSOLVING STRIP FOR ORAL MUCOSA AS A SYSTEMIC DRUG DELIVERY ROUTE - The invention relates to a dissolving strip for drug delivery providing a generally inert water soluble base material attached to the maxillary molars in order to deliver a therapeutic material upon activation by the parotid and other oral salivary glands. The composition of the dissolving strip is a generally inert base material, such as pullulan. The pullulan is impregnated with a therapeutic material to form a solid mixture to carry the therapeutic agent. The dissolving strip has sufficient flexibility to adhere to the 1-4 maxillary molars and acts as a reservoir to deliver therapeutic agents, such as an anti-smoking formula, a diet formula, a sexual enhancement formula, an oral freshness formula, prescription drugs, non-prescription drugs, herbs, or vitamins, or any combination of the previously listed. The dissolving strip is capable of delivering the therapeutic agents in a sustained or time released fashion. | 2010-07-08 |
20100172957 | EFLUCIMIBE MEDICAMENTS FOR PREVENTING/TREATING A DISEASE DUE TO SEBACEOUS GLAND DYSFUNCTION IN HUMANS OR ANIMALS - Administration of at least one compound selected from (S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetanilide (eflucimibe) of formula (I): | 2010-07-08 |
20100172958 | Wound dressing devices and methods - The present invention provides an absorbent wound dressing assembly that can be used to stanch, seal, or stabilize a site of tissue injury, tissue trauma, or tissue access. The wound dressing assembly is flexible so that it can be adapted and used to fit in narrow and small wound sites. Generally the wound dressing assembly comprises a flexible carrier material that is impregnated with a non-mammalian material for control of severe bleeding. The preferred non-mammalian material is poly [β-(1→4)-2-amino-2-deoxy-D-glucopyranose] more commonly referred to as chitosan. | 2010-07-08 |
20100172959 | RESERVOIR SYSTEM WITH CLOSED MEMBRANE - A dermal or transdermal therapeutic system comprising a reservoir that contains at least one active substance, an active substance-permeable membrane which delimits the active-substance reservoir, and a closing layer. The closing layer is impermeable to the active substance at a temperature lying below the skin temperature while being permeable at skin temperature and above. | 2010-07-08 |
20100172960 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES - The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may “crack” a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro-drug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or/and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases Alzheimer's diseases, Parkinson's diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon-rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers. | 2010-07-08 |
20100172961 | Encapsulated Peptide Amphiphile Nanostructures - The present invention provides compositions and methods for creating encapsulated peptide amphiphilic nanostructures useful in treating diseases. In particular, the present invention provides compositions and methods for preparing peptide amphiphile nanostructures that are encapsulated in liposomes by the application of light, and using such compositions in treating diseases, such as cancer. | 2010-07-08 |
20100172962 | THERAPEUTIC TARGETING OF INTERLEUKINS USING SIRNA IN NEUTRAL LIPOSOMES - The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides compositions that include an siRNA targeted to an interleukin and a neutral lipid, and methods of treating a human subject with cancer involving administering to the subject a pharmaceutically effective amount of an interleukin-8 antagonist or a composition as set forth herein. | 2010-07-08 |
20100172963 | MEDICINAL AGENT FOR TREATING PATIENTS SUFFERING FROM DISEASES CAUSED BY THE MONOAMINOOXIDASE EXCESSIVE ACTIVITY AND A METHOD FOR TREATING PATIENTS SUFFERING - The invention relates to the chemical and pharmaceutical industry and to medicine, in particular, to medicinal agents based on a mixture of natural oligomers of isoprenol (Ropren), which inhibits monoamine oxidase (MAO) activity; and to a method for treatment of patients suffering from diseases associated with the excessive activity of monoamine oxidase. | 2010-07-08 |
20100172964 | VESICLE USEFUL FOR EXTERNAL PREPARATION FOR SKIN, AND EXTERNAL PREPARATION FOR SKIN COMPRISING THE VESICLE - Disclosed is a technique for allowing an active ingredient as an agent for improving or maintaining the dermal environment to reach a dermis. Specifically disclosed is a vesicle comprising the following components 1) to 3): 1) an α,ε-bis(γ-N—(C | 2010-07-08 |
20100172965 | ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES - Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action. | 2010-07-08 |
20100172966 | Methods and compositions for cellular reprogramming - Compositions and methods useful for the treatment of aberrant programming diseases, particularly those associated with aberrant apoptosis are disclosed | 2010-07-08 |
20100172967 | COMPOUND MODIFIED WITH GLYCEROL DERIVATIVE - Objects of the present invention are to provide a compound which is useful as a surface modifier for producing a drug carrier or the like, or a salt thereof; a fine particle comprising the same; and the like. The present invention provides a compound in which a substance to be modified, which is selected from the group consisting of an amphiphilic substance and a hydrophobic substance, is modified with a glycerol derivative represented by the following formula (1): | 2010-07-08 |
20100172968 | CHIMERIC CANNULAE PROTEINS AND METHODS FOR MAKING AND USING THEM - A polymer is prepared by self-assembly of a plurality of monomeric polypeptide units. The polymer tends to form a nanotube and is capable of encapsulating a particular drug molecule. Once encapsulated in the polymer of the present invention, the drug molecule may be delivered to a particular location of human body to effectively cure a disease or treat a symptom. | 2010-07-08 |
20100172969 | HOT-MELT MICROPELLETS - The present invention provides a method of making solid micropellets of which at least 75% by weight have a diameter less than 500 μm comprising (i) melting one or more binders; and (ii) combining the one or more binders melted in step (i) with a pharmaceutically active ingredient to form solid micropellets. Solid micropellets obtainable by this method are also provided. The invention has particular utility for improving the solubility of poorly water-soluble pharmaceutically active ingredients. | 2010-07-08 |
20100172970 | ANTIVIRAL COMPOSITIONS - The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and subsequently milling said melt-extruded mixture. | 2010-07-08 |
20100172971 | Compositions for Inhibiting NADPH Oxidase Activity - Phycobilins are disclosed to have prodrug activity as inhibitors of NADPH oxidase activity and are disclosed to be useful in the prophylaxis and/or treatment of medical conditions associated with or linked to an NADPH oxidase activity. Compositions containing phycobilins are described which facilitate the administration of phycobilins. | 2010-07-08 |
20100172972 | ENTERIC COATED PHARMACEUTICAL COMPOSITIONS - The present invention relates to an enteric coated pharmaceutical composition comprising a core in the from of pellets comprising a therapeutically effective amount of duloxetine or its pharmaceutically acceptable salt, the pellets having a size between 700 to 1000 μm; a separating layer surrounding the core, comprising one or more pharmaceutically acceptable film-forming polymers and pharmaceutically acceptable excipient(s), the separating layer being present in an amount ranging from about 5% to about 20% by weight of the composition, and an enteric layer surrounding the separating layer comprising about 8% to about 25% by weight of the composition of poly(methacrylic acid, ethyl acrylate) (1:1) neutralized to a pH of about 5.0, wherein the enteric coated pharmaceutical composition, when administered orally to human subjects on an empty stomach, provides a maximum plasma concentration of duloxetine ranging from about 25 ng/ml to about 45 ng/ml, occurring from about 5 to 7 hours. | 2010-07-08 |
20100172973 | Pharmaceutical Composition - A pharmaceutical composition comprising an analgesic or analgesic combination and a stool softener is disclosed. The analgesic is selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, levorphanol, codeine, acetaminophen and combinations of these analgesics. The composition is formulated for oral administration as a liquid or solid dosage form for immediate, slow, delayed or sustained-release characteristics. | 2010-07-08 |
20100172975 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. | 2010-07-08 |
20100172976 | METHODS AND COMPOSITIONS FOR INHIBITING THE FUNCTION OF POLYNUCLEOTIDE SEQUENCES - A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell. In methods of treatment of prophylaxis of virus infections, other pathogenic infections or certain cancers, these compositions are administered in amounts effective to reduce or inhibit the function of the target polynucleotide sequence, which can be of pathogenic origin or produced in response to a tumor or other cancer, among other sources. | 2010-07-08 |
20100172977 | Abscisic acid against cancer - ABSCISIC Acid (ABA) a naturally occurring plant hormone has been identified in this invention with potent properties to fight cancer. ABA is able to produce a hyperpolarization condition on plasma membrane through a decrease of intracellular Na+ and K+. Such phenomenon is produced in cancer cells by mediation of ion channel and activation of the signaling g-protein pathway. ABA aborting sustained depolarization in malignant tissue will produce a change in the configurational state of cell from a damage to a normal state. additionally, a positive polarization of hCG outer layer accomplished through a removal of electrons will permit immune system cells coming close to cancer cells for destruction. | 2010-07-08 |
20100172978 | AQUEOUS COMPOSITION - Disclosed is an aqueous composition containing (a) an ethyl acrylate/methyl methacrylate copolymer or a plasticized vinyl accetate polymer, (b) an ethyl cellulose, (c) a water soluble additive for pharmaceutical products, (d) titanium oxide and (c) water. The solid content mass ratio among the components (a), (b), (c) and (d), namely a:b:c:d is 100:(5-50):(1-50):(0.5-10), and the solid content concentration in the aqueous composition is 0.5-40% by mass. | 2010-07-08 |
20100172979 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are controlled-release formulations containing a core comprising a core active agent (e.g., levetiracetam) and a wax excipient, where the core is substantially coated with an extended-release coating. | 2010-07-08 |
20100172980 | Tablet Containing Coated Particles of Cetirizine, Pseudoephedrine, and/or Naproxen - In one aspect, the present invention features a tablet including a first drug layer and a second drug layer, wherein: (i) the first drug layer includes first drug particles including naproxen and third drug particles including cetirizine, where the first drug particles and/or the third drug particles are coated with an immediate release coating; and (ii) the second drug layer including pseudoephedrine, wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours. | 2010-07-08 |
20100172981 | Ibuprofen-Effervescent Preparation Having a High Dissolution Rate and Method for the Production thereof - Effervescent ibuprofen formulations, which contain (a) an active ingredient-containing granule which contains a water-soluble ibuprofen salt and a basic excipient, and (b) an effervescent granule which contains an acid component and a carbon dioxide-forming component, and a process for their preparation. | 2010-07-08 |
20100172982 | SUSTAINED RELEASE FORMULATIONS OF DIVALPROEX SODIUM - A sustained release tablet formulation comprising an inner phase comprising a mixture of divalproex or its pharmaceutically acceptable salt and a hydrophobic agent, and an outer phase comprising a hydrophilic polymer, wherein the hydrophobic agent is present in amount ranging from 6.3% to about 8.3% by weight of the formulation. | 2010-07-08 |
20100172983 | Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole - The present disclosure is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The disclosure also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 2010-07-08 |
20100172984 | TABLET DOSAGE FORM COMPRISING CETIRIZINE AND PSEUDOEPHEDRINE - The present invention relates to a tablet dosage form comprising an immediate release component comprising cetirizine and an extended release component comprising pseudoephedrine. | 2010-07-08 |
20100172985 | Tablet Containing Cetirizine, Pseudoephedrine, and Naproxen Containing a Barrier Layer - In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer. | 2010-07-08 |
20100172986 | CONTROLLED RELEASE COMPOSITION AND PREPARATION THEREOF - The present invention relates to a controlled release composition comprising hydrophobic cellulose, methacrylic acid copolymer and active ingredient in a form of uniform state. The present invention also relates to a method of preparing a controlled release tablet. | 2010-07-08 |
20100172987 | Three Layer Tablet Containing Cetirizine, Pseudoephedrine, and Naproxen - In one aspect, the present invention features a tablet including a first drug layer, a second drug layer, and a third drug layer, wherein (i) the first drug layer includes naproxen; (ii) a second drug layer including pseudoephedrine; and (iii) the third drug layer includes cetirizine; wherein the first drug layer is in contact with the second drug layer, the third drug layer is in contact with the second drug layer, and the first drug layer is not in contact with the third drug layer, and wherein the second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours. | 2010-07-08 |
20100172988 | SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF - Disclosed is a sustained release preparation which comprises an active ingredient having a higher release rate at pH 4 compared to that in pH 1.2 or pH 6.8 and exerts a controlled release of the active ingredient in a pH-independent manner. The sustained release preparation comprises ethyl (−)-2-[4-[2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethyl-phenoxy]acetate hydrochloride as the active ingredient and a pH-independent gel-forming polymer and contains substantially no pH-controlling agent other than the polymer. The sustained release preparation can release the active ingredient in a pH-independent manner in the range from 1.2 to 6.8 and shows a constant release rate for a prolonged period of time. Therefore, the preparation is useful as a therapeutic agent for frequent urination/incontinence of urine which has a long-lasting effect. | 2010-07-08 |
20100172989 | ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION - The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. Most preferably, the dosage form includes verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release. | 2010-07-08 |
20100172990 | BIOCOMPATIBLE MICROGELS AND APPLICATIONS THEREOF - The biocompatible microgels comprises a polymeric network, said polymeric network comprising monomeric units interconnected with one another through a crosslinking agent, wherein said polymeric network can be obtained by polymerization in a dispersed medium of a biocompatible vinyl monomer and a crosslinking agent. The microgel may further comprise a biologically active agent. Said biocompatible microgels can be used, among other applications, to transport and dose biologically active agents. | 2010-07-08 |
20100172991 | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation - A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α | 2010-07-08 |
20100172992 | PATHOGENIC ATTENUATION VIA THE ADMINISTRATION OF AN EQUILIBIOTIC COMPOUND - A pharmaceutical preparation comprising as an active ingredient micron-sized sulphur particles [−(300 microns]. The pharmaceutical preparation further comprises an excipient, i.e. a sodium lignin sulphate or other suitable agents. The preparation is used for the prevention and treatment of pathogenic disorders in humans and animals, in a nutritional and/or supplemental regime, as well as, to improve feed and reproductive performance. A variety of conditions were treated including: pneumonia, arthritis, ulcers, diabetes mellitus, GI cancer, lupus, herpes, psoriasis and early menopause. | 2010-07-08 |
20100172993 | PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF - The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms. | 2010-07-08 |
20100172994 | Nanoparticles for Protection of Cells from Oxidative Stress - The present invention concerns metal oxide semiconductor nanoparticles with free radical scavenging activity, compositions comprising such nanoparticles, methods for their use, and methods for their production. In one aspect, the invention concerns a method for enhancing the survival or viability of transplanted cells, comprising administering an effective amount of metal oxide semiconductor nanoparticles to a target anatomical site of a subject before, during, or after administration of transplant cells to the subject. Preferably, the metal oxide nanoparticle is a cerium oxide (ceria) nanoparticle. | 2010-07-08 |
20100172995 | Process For Preparing A Solid Pharmaceutical Composition - The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof which avoids a wet granulation step and results in very stable pharmaceutical compositions, like tablets. | 2010-07-08 |
20100172996 | Chain-End Functionalized Methoxy Poly(Ethylene Glycol) and Metal Nano-Particles Using the Same - Disclosed is a chain-end functionalized methoxy poly(ethylene glycol) (mPEG), a process of preparing the same, a living methoxy poly(ethylene glycol) for preparing the functionalized methoxy poly(ethylene glycol), a nano-particles of transition metal or metal salt encapsulated in the micelle structure formed by the chain-end functionalized methoxy poly(ethylene glycol), and a method for preparing the nano-particles of transition metal or metal salt. | 2010-07-08 |
20100172997 | GOLD, SILVER, AND COPPER NANOPARTICLES STABILIZED IN BIOCOMPATIBLE AQUEOUS MEDIA - The present invention includes metal nanoparticles composition and methods of making and using the same by converting a metal (I) to a metal (0) and forming one or more metal nanoparticles from the metal (0). The one or more metal nanoparticles are stabilized with one or more biocompatible stabilizers to prevent agglomeration and make them amenable for biomedical applications. | 2010-07-08 |
20100172998 | PROCESS FOR PREPARING MICROPARTICLES THROUGH PHASE INVERSION PHENOMENA - A process for preparing nanoparticles and microparticles is provided. The process involves forming a mixture of a polymer and a solvent, wherein the solvent is present in a continuous phase and introducing the mixture into an effective amount of a nonsolvent to cause the spontaneous formation of microparticles. | 2010-07-08 |
20100172999 | Polynuclear Microcapsules - A process is disclosed for preparing polynuclear microcapsules by polymerizing an alkoxysilane at the oil/water interface of a multiple phase emulsion to form a suspension of polynuclear microcapsules. Also disclosed are polynuclear micro-capsules optionally comprising a hydrophilic active and uses thereof. | 2010-07-08 |
20100173000 | Controlled release implantable dispensing device and method - A dispensing device having a polymer which is combined with a therapeutic agent in the form of a microparticle or nanoparticle which is “hyper-compressed” to form a controlled release dispensing device and methods of locally administering a therapeutic agent using said microparticles. | 2010-07-08 |
20100173001 | Metal Ion-Treated Biocompatible Polymers Useful for Nanoparticles - Disclosed are methods for forming particles useful for the treatment of hyperproliferative disease. The method includes providing a bioactive component and a metal ion-treated biocompatible polymer component; coating the bioactive component with a surfactant having an HLB value of less than about 6.0 units under conditions which form a coated bioactive component; associating the coated bioactive component with the a metal ion-treated biocompatible polymer under conditions which associate the coated bioactive component with the metal-ion treated biocompatible polymer to form a particle, where the particles have an average diameter of less than about 50 nanometers. Related compositions and methods to treat disease using the particles are also disclosed. | 2010-07-08 |
20100173002 | Microcapsules with improved shells - Disclosed are microcapsules and methods for preparing and using them, as well as methods for improving various properties of microcapsules like impermeability. | 2010-07-08 |
20100173003 | COMPOSITION AND METHOD FOR ENCAPSULATING BENEFIT AGENTS - A benefit agent encapsulated in a particulate-based encapsulant, and a method of manufacturing the encapsulated benefit agent, are disclosed. | 2010-07-08 |
20100173004 | PREVENTIVE AND THERAPEUTIC VACCINE FOR ALZHEIMER'S DISEASE - A method for producing theraputic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) microparticles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer, Parkinson, Huntington, Amyloid lateral sclerosis(ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Alzheimer's in animals and its practicability for therapy in humans. | 2010-07-08 |
20100173005 | MICROPARTICLE FORMULATIONS FOR SUSTAINED-RELEASE OF BIOACTIVE COMPOUNDS - A composition is provided for administration to a subject by way of a needleless syringe. The composition is formed from particles having a mean mass aerodynamic diameter of from 1 to 250 microns, and an envelope density of from 0.1 to 25 g/cm.sup.3, where the particles include a biologically active agent and a sustained-release material that controls release of the active agent to a subject following administration of the composition thereto. Methods for delivering a biologically active agent to a subject are also provided. | 2010-07-08 |
20100173007 | COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS IN MAMMALS - A topical composition for treating skin diseases is provided. The composition comprises | 2010-07-08 |
20100173008 | METHOD OF TREATING OR ALLEVIATING THE SYMPTOMS OF ALESION IN MAMMAL - Provided is a new use of Brown's gas, more particularly, to the use of Brown's gas for the treatment of diseases in mammals and a Brown's gas supply apparatus therefor. It is based on the assumption that the Brown's gas is a medium capable of directly supplying moisture (special form of water according to the third theory of Brown's gas) to many regions of the body via skin, etc. Various effects of the Brown's gas on the body have been demonstrated. In particular, provided is a new use of the Brown's gas for treatment or alleviation of the symptoms of a lesion in a lesional tissue, cell, or organ of a mammal. Provided is also a simple and inexpensive Brown's gas supply apparatus for supplying pure Brown's gas suitable to be applied to the human body. | 2010-07-08 |
20100173009 | SILICATE-SUBSTITUTED HYDROXYAPATITE - An inorganic silicate-substituted calcium phosphate hydroxyapatite, useful as a biomaterial, has a Ca/P molar ratio in the range 2.05 to 2.55 and a Ca/(P+Si) molar ratio less than 1.66. The hydroxyapatite can be substantially free of carbonate ions. The material has relatively high solubility and is able to release silicon into solution. | 2010-07-08 |
20100173010 | Polymetaphosphate based formulations for therapy of microcrystalline arthropathies - Soluble pharmaceutical composition for the treatment of articular pathologies comprising an effective amount of a least one linear or cyclic polymetaphosphate or a soluble and pharmaceutically acceptable salt thereof, and appropriate diluents. | 2010-07-08 |
20100173011 | DISINFECTANT CLEANING COMPOSITION AND METHOD - The present invention relates to the field of cleaning compositions for cleaning various surfaces, and to a method of cleaning such surfaces. In one embodiment, the present invention relates to surface cleaning compositions which include a disinfectant and a method of cleaning surfaces such as hard and soft surfaces. | 2010-07-08 |
20100173012 | METHODS FOR TREATING AN APPLE TREE INFECTED WITH VENTURIA INAEQUALIS - A method of treating an apple orchard to reduce infection of the apple orchard by | 2010-07-08 |
20100173013 | TREATMENT OF NEOPLASTIC DISORDERS USING COMBINATION THERAPIES - The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic disorders. | 2010-07-08 |
20100173014 | METHODS OF MAKING AND USING NANO SCALE PARTICLES - The instant invention discloses methods of preparing phospholipid delivery systems encapsulating one or more bio-affecting compounds, said methods comprising solubilizing a heterogeneous phospholipid mixture into a suitable organic solvent to form a concentrated formulation of phospholipids, wherein the phospholipids comprise a charged phospholipid species, and mixing the concentrated formulation with an aqueous solution comprising at least one bio-affecting compound. The instant invention also discloses methods of using a phospholipid delivery system encapsulating at least one bio-affecting compound for administration to an individual in need thereof. | 2010-07-08 |
20100173015 | COMPOSITIONS AND METHODS FOR THE ABSORPTION, CHELATION, AND ELIMINATION OF TRACE ELEMENTS - This invention relates to compositions and methods effective for the absorption, chelation and elimination of trace elements, in particular tin, mercury, aluminium, cadmium, lead, and other metals, metaloids and lanthinides. It is comprised of dihydroquercetin and zeolite, with or without humic and fulvic acids. The combination acts as a powerful chelator and eliminator of toxic trace elements and enhances their absorption from the intestine, blood, and organs, and may be administered for the absorption, chelation and elimination of toxic or potentially toxic trace elements including metals and metalloids, and lanthinides. | 2010-07-08 |
20100173016 | COMPOSITIONS AND METHODS FOR THE ABSORPTION, CHELATION, AND ELIMINATION OF TRACE METALS - This invention relates to compositions and methods effective for the absorption, chelation and elimination of trace elements, in particular tin, mercury, aluminium, cadmium, lead, and other metals, metaloids and lanthinides. It is comprised of dihydroquercetin and zeolite, with or without humic and fulvic acids. The combination acts as a powerful chelator and eliminator of toxic trace elements and enhances their absorption from the intestine, blood, and organs, and may be administered for the absorption, chelation and elimination of toxic or potentially toxic trace elements including metals and metalloids, and lanthinides. | 2010-07-08 |
20100173017 | Method of manufacturing skin care cream containing baked shell powder - In a method of manufacturing a skin care cream containing baked shell powder, highly calcium-containing shells such as dead shells or pearls is baked and crushed to fine powder to obtain baked shell powder. Then, the obtained baked shell powder is added to mix with a raw material for manufacturing cosmetic cream. | 2010-07-08 |
20100173018 | Microbicidal Compositions Including Activated Nitrogenous Compound and 1,4-Bis(Bromoacetoxy)-2-Butene, and Methods Of Using The Same - Microbicidal compositions for aqueous systems are provided that include (a) a nitrogenous compound activated by an oxidant or an enzyme and (b) 1,4-bis(bromoacetoxy)-2-butene (BBAB). The components are present in a combined amount synergistically effective to control the growth of at least one microorganism. Methods for controlling the growth of microorganisms in aqueous systems with the compositions are also provided. | 2010-07-08 |
20100173019 | METHOD OF STABILIZING HUMAN EYE TISSUE BY REACTION WITH NITRITE AND RELATED AGENTS SUCH AS NITRO COMPOUNDS - A method for stabilizing collagenous eye tissues by nitrite and nitroalcohol treatment. The topical stiffening agent contains sodium nitrite or a nitroalcohol in a buffered balanced salt solution and can be applied to the surface of the eye on a daily basis for a prolonged period. Application of the solution results in progressive stabilization of the corneal and scleral tissues through non-enzymatic cross-linking of collagen fibers. The compounds can penetrate into the corneal stroma without the need to remove the corneal epithelium. In addition, ultraviolet light is not needed to activate the cross-linking process. The resulting stabilization of corneal and scleral tissues can prevent future alterations in corneal curvature and has utility in diseases such as keratoconus, keratectasia, progressive myopia, and glaucoma. | 2010-07-08 |
20100173020 | USES OF AMMONIUM CHLORIDE - A method to treat a condition in a patient comprising administering to the patient a therapeutically effective amount of a NH | 2010-07-08 |
20100173021 | Topical Product formulations containing strontium for reducing skin irritation - Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed. | 2010-07-08 |
20100173022 | COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS AND METABOLIC SYNDROME - The invention relates to the field of pharmacology. More specifically, the invention relates to a composition for the treatment of diabetes mellitus and/or the metabolic syndrome. Even more specifically, the invention relates to a herbal composition for treating the same. In one of its embodiments, the invention provides a composition comprising a) an anti hyperglycaemic agent b) an anti inflammatory agent c) an anti hyperlipidemic agent d) an anti oxidant agent e) a gastro-intestinal agent, wherein said activities are provided by parts or extracts of | 2010-07-08 |
20100173023 | Medical herb composition for inhibiting shedding of a mammal's hair and method for preparing the same - The present invention relates to a medical herb composition for reducing shedding of mammal hair and a method for preparing the same. The medical herb composition comprises: a first herb material selected from the group consisting of Ginseng Radix, Astragali Radix, Batatatis Rhizoma, Zizyphi Fructus, | 2010-07-08 |
20100173024 | METHODS AND COMPOSITIONS FOR ALTERING HEALTH, WELLBEING, AND LIFESPAN - Described herein are the results of comprehensive genetic expression and other molecular analysis of the effect of antioxidants on biological systems, including specifically different human cells. Based on these analyses, methods and compositions are described for modifying or influencing the lifespan of cells, tissues, organs, and organisms. In various embodiments, there are provided methods for modulating the activity of the gene maintenance process in order to influence the length and/or structural integrity of the telomere in living cells, as well as methods for modulating the rate/efficiency of the cellular respiration provided by the mitochondria, mitochondrial biogenesis, and maintenance of the mitochondrial membrane potential. Exemplary lifespan altering compounds include natural and synthetic antioxidants, such as plant antioxidant and polyphenol compounds derived from coffee cherry, tea, berry, and so forth, including but not limited to caffeic acid, chlorogenic acid, ferulic acid, quinic acid, proanthocyanidins, ubiquinone, idebenone, or a synthetic form or derivatives thereof. | 2010-07-08 |
20100173025 | FAT ABSORPTION INHIBITORY COMPOSITION - The present invention provides a composition that exhibits favorable fat absorption inhibitory activity, is capable of being safely and easily taken continuously without side effects, and further is capable of preventing and/or improving conditions associated with excessive fat absorption such as obesity and hyperlipidemia. The present invention relates to a fat absorption inhibitory composition, which contains as an active ingredient a component that is collected as insoluble matter obtained by extracting wheat germ with water at 65° C. or lower and pH 5.0 or lower and treating the extract at 70° C. or higher and pH 6.0 or higher. | 2010-07-08 |